1. Scrip
  2. >>Market Snapshot

Sickle Cell Disease Market Snapshot: "The Time Has Come"

 
• By Jessica Merrill

Three new drugs for sickle cell disease could be on the market in the US next year, representing a groundswell of advancement for the devastating blood disorder that has had limited options.

Hand flip wooden cube with word change to chance, Personal development and career growth or change yourself concept - Image
Big changes are in store for the sickle cell disease treatment market • Source: Shutterstock

With one new drug on the market in the US and two more pending at the US Food and Drug Administration, 2020 is positioned to be a turning point for the treatment of sickle cell disease. Patients with the devastating blood disorder, which results in acute pain crises, long-term organ damage and a shortened lifespan, have had few treatment options, but the outlook for sickle cell R&D is brighter than it has been.

"The time has come. We are at the cusp of improving the quality of life for people with sickle cell...

More from Market Snapshot

More from Scrip

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 
• By Andrew McConaghie

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.